Article
Emerging therapies for acute myeloid leukemia: translating biology into the clinic.
JCI insight - 21 Sept 2017
Kavanagh Simon, Murphy Tracy, Law Arjun, Yehudai Dana, Ho Jenny M, Chan Steve, Schimmer Aaron D
Abstract excerpt
Acute myeloid leukemia (AML) is an aggressive hematological malignancy with a poor outcome; overall survival is approximately 35% at two years and some subgroups have a less than 5% two-year survival. Recently, significant improvements have been made in our understanding of AML biology and genetics. These fundamental discoveries are now being translated into new therapies for this disease. This review will...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
